摘要
新生儿缺血缺氧性脑损伤(hypoxic-ischemic brain damage,HIBD)常伴随着高死亡率和严重的功能障碍如儿童脑瘫、智力低下等,对许多家庭造成极大的经济损失及精神损伤,破坏家庭的和谐,早已引发广大研究者的关注及重视。但就目前研究来看,其发病机制还可进一步阐述及寻找新的有效治疗方法。促红细胞生成素(erythropoietin,EPO)是临床应用比较有前景的治疗药物,目前并未被广泛用于新生儿HIBD治疗。本综述将结合近年来国内外研究现状,从新生儿HIBD的发病机制等探讨EPO治疗新生儿HIBD的现状及前景。
Neonatal hypoxic-ischemic brain damage（HIBD）is often associated with high mor-tality and serious disorders such as cerebral palsy and mental retardation.It has caused the atten-tion of many researchers due to its enormous influences on economics,mentality and harmony of families.However,the pathogenesis and effective treatment of HIBD still need further investiga-tion.Erythropoietin （EPO）,a promising clinical drug,is not widely used in the treatment of HIBD.This paper reviews the pathogenesis of HIBD and current status and prospect of EPO for HIBD.
出处
《南昌大学学报（医学版）》
CAS
2017年第5期94-97,共4页
Journal of Nanchang University：Medical Sciences
